Figure 2
From: Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
(A-C) Viability of UM-UC-3, UM-UC-6, UM-UC-9 cells treated with different concentrations of dacomitinib was measured by the blue titer assay (fluorescent intensity units). Difference between dacomitinib concentrations ≥50 nmol/L (UM-UC-6), ≥ 100 nmol/L (UM-UC-9) and DMSO (control) was significant (p < 0.001; p < 0.05); difference was less significant in UM-UC-3 cells (p < 0.05). (D) Viability of UM-UC-6 cells treated once with 2 µmol/L dacomitinib (Dac), 2 or 10 µmol/L cetuximab (Cet), 2 or 10 µnmol/L trastuzumab (Tst), DMSO. Difference between each inhibitor versus DMSO was significant (p < 0.01) except for 2 µmol/L TST. Dac was superior to 2 µnmol/L TST (p = 0.0005), 2 µmol/L Cet (p = 0.042). Dac did not significantly differ than 10 µmol/L Cet, and combination of 2 µmol/L Cet + 2 µmol/L Tst. (E) Viability of UM-UC-6 cells treated once with 2 µmol/L dacomitinib, 2 µmol/L lapatinib, DMSO. Difference between each inhibitor versus DMSO was significant (p < 0.001); difference between inhibitors was not significant. (F) Apoptosis measured by caspase 3/7 cleavage luminogenic assay in UM-UC-6 cells treated with 2 µmol/L dacomitinib (Dac), DMSO (negative control), 0.5 µmol/L staurosporin (Sts; positive control).